Translate page

Marc Delord






Burden of CML in China and India:
The rising incidence and prevalance of the disease
Marc Delord, Université Paris Diderot, France 

  • Basic CML epidemiology
  • India and China demographics
  • Incidence of CML in India and China
  • Prevalence of CML in India and China
  • Conclusions and perspectives


Collage VEP Ross White

  Dr David Ross     Dr Deborah White




 Session 3: Future directions for CML

  • TFR trial update 
    (Dr David Ross)
  • Biomarkers and response prediction 
    in CML
    (Dr Deborah White)



David Yeung 3Devendra HiwaseAgnes YONG w labcoat1

Dr David Yeung        Dr Devendra Hiwase     Dr Agnes Yong



Session 2: TKI resistance / failure

  • When frontline therapy fails 
    (Dr David Yeung)
  • CML - beyond chronic phase
    (Dr Devendra Hiwase)
  • Allograft - still a role in CML?
    (Dr Agnes Yong)


Timothy Hughes.png

Prof. Tim Hughes


 Session 1: Frontline CML

  • Current clinical issues 
    (Prof. Tim Hughes)



EHA Jane Apperley





Treatment Outcomes on Bosutinib: Data from the Real World
Jane Apperley, Imperial College, London, UK

  • Change in CML survival over time: German studies 
  • Patient pathways for tyrosine kinase inhibitors
  • Introduction of bosutinib into clinical practice
  • Real-World use of bosutinib: UK & Netherlands
  • Responses to bosutinib in chronic phase
  • Reasons for discontinuation of bosutinib
  • Disease progression
  • Adverse events on bosutinib
  • Overall survival
  • Summary and conclusions

This presentation is adapted from one given during the industry sponsored symposium at EHA.


EHA Delphine Rea






Factors affecting clinical decision making in refractory and relapsed CP-CML patients
Delphine Réa, Centre Hospitalo-Universitaire Saint-Louis, Paris, France

  • TKI resistance: significance and definition 
  • BCR-ABL1 mutations and resistance to imatinib and 2nd generation TKI's
  • Failure of 1st and 2nd generation TKI's
  • Mortality and causes of death in CP-CML patients during 2nd or subsequent line TKI
  • Responses to 3rd line therapy after resistance or intolerance to 2nd generation TKI
  • 5-year results from the PACE study: Responses to ponatinib in CP-CML patients
  • Therapeutic innovation: allosteric inhibition of BCR-ABL1 by ABL001
  • Conclusion and perspective

This presentation is adapted from one given during the industry sponsored symposium at EHA.